Key facts
- This page summarizes Brian Goff's Form 4 filing for AGIOS PHARMACEUTICALS, INC. (AGIO).
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 03 Mar 2023, 15:06.
Brian Goff - 01 Mar 2023 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)
- Reporting relationship
- Chief Executive Officer, Director
- Issuer ticker
- AGIO
- Reported as of
- 01 Mar 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 03 Mar 2023, 15:06:20 UTC
- Prior SEC filing
- 09 Aug 2022
- Next SEC filing
- 30 Jun 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ William Cook, as Attorney in Fact for Brian Goff
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Brian Goff filed Form 4 for AGIOS PHARMACEUTICALS, INC. (AGIO) on 03 Mar 2023.
Change
- Previous filing in this sequence was filed on 09 Aug 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
AGIO
transaction
Derivative
Restricted stock units
Award
- Transaction value
- $0
- Shares
- +25,500
- Change %
- Price
- $0.000000
- Shares after
- 25,500
- Date
- 01 Mar 2023
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 25,500
- Exercise price
- Footnotes
- F1, F2
AGIO
transaction
Derivative
Stock options (right to buy)
Award
- Transaction value
- $0
- Shares
- +94,500
- Change %
- Price
- $0.000000
- Shares after
- 94,500
- Date
- 01 Mar 2023
- Ownership
- Direct
- Underlying class
- Common stock
- Underlying amount
- 94,500
- Exercise price
- $25.01
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
Footnote F2
The restricted stock units were granted on March 1, 2023. Beginning on March 1, 2024, the shares underlying the restricted stock units will vest in three equal annual installments.
Footnote F3
This option was granted on March 1, 2023. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2024, with the remaining 75% vesting in 36 equal monthly installments thereafter.